All In Vivo Testing articles
-
NewsMenin inhibitor KO-7246 shows β-cell regeneration in preclinical diabetes models
New preclinical data suggests that menin inhibitor KO-7246 can regenerate functional pancreatic β-cells and sustain improvements in blood glucose control across both Type 1 and Type 2 diabetes models.
-
NewsIn vivo CAR T review charts path to off-the-shelf cellular therapy
A review from researchers at Naval Medical University and Shanghai Jiao Tong University examines how engineering CAR T cells directly inside the body could cut manufacturing complexity and expand patient access to cellular immunotherapy.
-
NewsExperimental drug reverses paralysis and vision loss in MS mice
A novel inflammasome inhibitor derived from HIV antivirals has reversed established neurological deficits in a preclinical MS model, raising hopes for a restorative approach to a disease where current therapies focus primarily on relapse prevention.
-
NewsVaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
-
NewsBCG and immunotherapy combination cuts tuberculosis relapse risk
Combining the BCG vaccine with a B-cell-targeting immunotherapy significantly reduced tuberculosis relapse rates in preclinical models.
-
NewsLiver cancer organoids used to screen 1,600 potential treatments
Researchers at the University of Basel have screened more than 1,600 compounds using a biobank of 35 hepatocellular carcinoma organoids, identifying drug combinations that show selective anti-tumour activity across biologically diverse liver cancers.
-
NewsWhy researchers are targeting Nav1.7 in the search for longer-lasting pain relief
Humanised antibodies targeting the voltage-gated sodium channel Nav1.7 have demonstrated prolonged suppression of neuropathic pain in a rat model.
-
NewsExperimental RNA drug reverses scleroderma signs in preclinical study
An experimental synthetic non-coding RNA drug has reversed signs of systemic sclerosis in patient-derived immune cells and mouse models, with researchers now preparing an IND application to the FDA.
-
NewsWhy cancer drug CADD522 could offer a new route to treating osteoporosis
A compound originally designed to block a cancer-associated protein has demonstrated unexpected benefits for bone health and metabolism in post-menopausal mice, suggesting a potential new mechanism for osteoporosis drug discovery.
-
NewsGLP-1 drug semaglutide extends lifespan and slows ageing in older mice
A new NIH-funded study suggests the GLP-1 receptor agonist semaglutide may slow biological ageing and extend lifespan in older mice, raising the prospect that GLP-1 drugs could one day be developed as broad longevity-enhancing interventions.
-
NewsEngineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
A preclinical study combining chemically modified suppressor tRNAs with inhaled lipid nanoparticles has restored functional CFTR protein production across bronchial epithelial cells, mouse models and patient-derived organoids, offering a potential new therapeutic strategy for nonsense mutation-driven cystic fibrosis.
-
NewsHER3-DXd and olaparib combination boosts lung cancer treatment responses
A new preclinical study finds that combining the antibody-drug conjugate HER3-DXd with PARP inhibitor olaparib significantly improves treatment responses in NSCLC models, including those harbouring EGFR and KRAS mutations, by overwhelming DNA repair capacity and activating innate immune signalling.
-
NewsExhausted T cells escape tumours to drive lasting cancer immunity
A preclinical study has identified a subset of exhausted, LAG3-expressing T cells capable of migrating out of tumours to establish long-term immune memory, with potential implications for LAG3-targeting cancer immunotherapies.
-
NewsAutomated MRI pipeline standardises preclinical stroke damage measurement
An automated imaging pipeline developed at USC’s Stevens Neuroimaging and Informatics Institute can measure stroke-related brain tissue damage from MRI scans with accuracy matching human experts, offering a scalable, standardised tool for preclinical drug evaluation across multi-site research networks.
-
NewsMeis2 gene identified as potential therapeutic target for neurodevelopmental disorders
A gene therapy targeting parvalbumin inhibitory neurons has restored experience-dependent plasticity and reduced seizure frequency in a mouse model of neurodevelopmental disorders, offering a potential new avenue for treating autism spectrum disorder and epilepsy.
-
NewsVY1706 Alzheimer’s gene therapy achieves 75 percent tau reduction in preclinical study
Voyager Therapeutics has presented six-month GLP toxicology data for VY1706, its investigational tau-targeting gene therapy, showing durable tau reductions of up to 75 percent and a clean safety profile in non-human primates, as the company prepares to begin first-in-human dosing in the second half of 2026.
-
NewsTriple drug combination targets cancer and senescent cells simultaneously
A three-drug combination targeting shared metabolic vulnerabilities in cancer and senescent cells has improved physical performance and extended survival in aged mice, whilst avoiding the thrombocytopenia associated with existing navitoclax-based regimens.
-
NewsOral antiviral GHP-88310 candidate shown to block measles transmission in ferret model
An experimental oral antiviral has demonstrated the ability to prevent both airborne and contact-based transmission of a measles surrogate virus in ferrets, offering a potential new tool to complement vaccination during outbreaks.
-
NewsInsilico Medicine nominates ISM9528 non-opioid chronic pain candidate using AI
Insilico Medicine has nominated ISM9528, an orally available, brain-penetrant non-opioid candidate targeting a previously unrecognised pain mechanism, as its 31st AI-generated preclinical compound since 2021, with efficacy exceeding morphine in some preclinical models.
-
NewsNew bispecific T cell engager platform targets ovarian cancer in preclinical studies
Scientists at The Wistar Institute have engineered a DNA-delivered bispecific T cell engager using a ‘knob-into-hole’ antibody platform, demonstrating improved persistence and dual-antigen targeting in preclinical ovarian cancer models.